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There are several U.S. FDA-cleared molecular respiratory virus panels available today, each with advantages and disadvantages.
This study compares four multiplex panels, the BioFire Diagnostics FilmArray RP (respiratory panel), the GenMark Dx eSensor
RVP (respiratory viral panel), the Luminex xTAG RVPv1, and the Luminex xTAG RVP fast. Three hundred specimens (200 ret-
rospective and 100 consecutive) were tested using all four platforms to determine performance characteristics. The overall sensi-
tivity and specificity, respectively, and 95% confidence interval (CI; in parentheses) for each panel were as follows: FilmArray RP,
84.5% (79.2, 88.6) and 100% (96.2, 100); eSensor RVP, 98.3% (95.5, 99.5) and 99.2% (95.4, 100); xTAG RVPv1, 92.7% (88.5, 95.4)
and 99.8% (96.0, 100); and xTAG RVP fast, 84.4% (78.5, 88.9) and 99.9% (96.1, 100). The sensitivity of each assay fluctuated by
viral target, with the greatest discrepancies noted for adenovirus and influenza virus B detection. Hands-on time and time to
result were recorded and ease of use was assessed to generate a complete profile of each assay.
Respiratory viral infections remain a leading cause of medicalvisits and can contribute significantly to morbidity and mor-
tality. Most respiratory viruses present with similar symptoms,
making a diagnosis difficult without laboratory testing. Accurate
and timely identification of respiratory viruses benefits the pa-
tient, particularly when the pathogen is one for which therapy
exists, such as influenza viruses (1). Additional benefits of respi-
ratory viral identification include epidemiologic tracking of local
outbreaks or epidemics, applying appropriate infection control
measures to admitted patients (e.g., droplet and/or contact pre-
cautions and considerations in creating cohorts), and decreasing
the use of unnecessary antimicrobial therapy, when appropriate
(2, 3).
Current diagnostic techniques for the detection and identifica-
tion of respiratory viruses are somewhat limited. Although rapid
antigen testing offers quick results, the sensitivity and specificity of
rapid antigen testing vary greatly (4, 5). The sensitivities of two
rapid influenza virus tests for the detection of influenza virus
A/H1N1/2009 averaged 21% (6), and respiratory syncytial virus
(RSV) rapid antigen sensitivity as low as 59% has been reported
(7). Direct fluorescent antibody testing and viral culture have a
greater degree of sensitivity and have the advantage of detecting
several viruses simultaneously; however, both are time consuming
and demand significant experience to perform the testing and
correctly interpret the results. To close the gap between sensitivity
and time to result, amplification-based technologies have been
developed. Several nucleic acid amplification tests are available as
in vitro diagnostics for respiratory virus detection. Some assays
only detect a single viral type, such as adenovirus (AdV) (Hologic
Gen-Probe, San Diego, CA), parainfluenza viruses (PIV) (Hologic
Gen-Probe), metapneumovirus (MPV) (Hologic Gen-Probe and
Quidel, San Diego, CA), and influenza viruses (Cepheid, Sunny-
vale, CA; IQuum, Marlborough, MA; and Qiagen, Gaithersburg,
MD). Other assays offer limited multiplex testing, such as for in-
fluenza viruses and RSV (Focus Diagnostics, Cypress, CA; Nano-
sphere, Northbrook, IL; and Hologic Gen-Probe) and for RSV and
metapneumovirus (Quidel). Currently, four molecular multiplex
respiratory virus panels for the simultaneous detection of more
than three respiratory viruses have been cleared by the U.S. FDA,
namely, the FilmArray RP (respiratory panel) (BioFire Diagnos-
tics, Salt Lake City, UT), the eSensor RVP (respiratory viral panel)
(GenMark Dx, Carlsbad, CA), the Luminex xTAG RVPv1, and the
Luminex xTAG RVP fast (Luminex Molecular Diagnostics, Aus-
tin, TX). Table 1 summarizes the details of these four FDA-cleared
assays.
Studies comparing these molecular multiplex platforms to in-
house molecular methods have found overall sensitivities and
specificities, respectively, of 89.4% and 99.6% for the FilmArray
RP (8), 95.4% and 99.7% for the eSensor RVP (9), 91.2% and
99.7% for the xTAG RVPv1 (10), and 78.8% and 99.6% for the
xTAG RVP fast (11). Although there are additional published data
on the performance of each of these four respiratory platforms, it
is difficult to compare assay performance among the multiplex
panels since the comparative method varies from study to study
(12–17). To our knowledge, there has not been a comprehensive
analysis of how these multiplex respiratory viral panels compare
to each other. This study aims to compare the four FDA-cleared
molecular multiplex respiratory viral panels with regard to sensi-
tivity, specificity, and workflow parameters, such as hands-on
time, time to result, and relative ease of use.
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MATERIALS AND METHODS
Study specimens. The nasopharyngeal (NP) swab specimens (n  300)
used in this study were collected from 294 symptomatic patients. Speci-
mens were from the following age groups: 5 years (n  105), 6 to 11
years (n  31), 12 to 17 years (n  18), and 18 years (n  146). Positive
(n  161) and negative (n  39) retrospective specimens (n  200) were
collected between August 2007 and November 2011, and consecutive
specimens (n  100) were collected in January 2012. Retrospective spec-
imens were tested at the time of collection by the method requested by the
clinician (laboratory-developed test [LDT], n  72; xTAG RVPv1, n  83;
LDT and xTAG RVPv1, n  6; viral culture, n  1; Xpert Flu [Cepheid,
Sunnyvale, CA], n  38). The consecutive specimens were initially as-
sayed using the xTAG RVPv1. Flocked swabs transported in universal
transport medium (Becton, Dickinson, Sparks, MD) were used for all NP
specimens collected starting in 2009. Otherwise, routine NP swabs in viral
transport medium (Remel, Lenexa, KS) were used. All specimens were
stored at 70°C. A true prospective study could not be performed due to
the inability to predict the time period with greatest respiratory virus
prevalence and variability. Consequently, we archived all NP swabs sub-
mitted for respiratory virus panel testing between November 2011 and
April 2012 at 70°C. The positivity rate and number of circulating viruses
was later determined to be highest in mid-January (35% positivity and 7
viruses circulating). Therefore, to mimic a prospective study, 100 consec-
utive NP swabs received beginning on 9 January 2012 were retrieved from
the freezer for study inclusion.
Respiratory virus testing. All NP swabs were tested with the four
respiratory viral panels according to their respective package inserts. Ex-
traction, when required, was performed using the bioMérieux EasyMag
(Durham, NC) and was completed within 24 h of the samples being
thawed. The assays were initiated within 24 h of extraction. Samples were
kept at 4°C until all testing was complete, which occurred in less than 5
days. Standard eSensor and xTAG batches consisted of 21 specimens plus
applicable controls. Process controls included the addition of bacterio-
phage MS-2 to all samples prior to extraction; bacteriophage lambda was
used as a run control for the xTAG assays, as well as external positive and
no-template controls. The FilmArray RP contained its own internal con-
trols within each pouch—an RNA process control and a second-stage
PCR control. Time studies were conducted by two technologists indepen-
dently logging elapsed times for each step of the assay over the course of
two to three batches; mean times are reported.
Reference result. The interpretation of results was performed accord-
ing to the individual package inserts. Those specimens with indeterminate
or equivocal results were repeated according to the manufacturers’ sug-
gestions (FilmArray, n  1, GenMark, n  3, and xTAG RVPv1, n  13).
If the repeat result was positive or negative, the final result was docu-
mented as the second result obtained as recommended by the manufac-
turers. However, if the sample was again indeterminate/equivocal, the
sample was excluded from the sensitivity analysis (n  1), with the excep-
tion of the observed parainfluenza virus 1 (PIV1) and PIV3 cross-reactiv-
ity on the xTAG RVPv1, discussed below. These results were recorded as
PIV3 positive only. A true positive was defined as being positive by two or
more of the platforms used or positive by a laboratory-developed test. The
xTAG assays were considered one platform (xTAG RVPv1 and xTAG RVP
fast) for the purposes of defining a true positive. LDTs were available for
adenovirus (18), enterovirus (EV) (19), influenza virus A and B (20), and
RSV A and B (21). We previously determined that the enterovirus LDT
does not cross-react with rhinovirus (RhV) (data not shown). LDTs were
performed when there was not a positive consensus from the multiplex
platforms (i.e., only one platform was positive). Adenovirus typing was
performed by sequencing the hexon gene according to the protocol of Lu
and Erdman (22). The Prodesse ProFAST assay (Hologic Gen-Probe)
was performed according to the recommendations in the manufacturer’s
package insert for influenza virus A subtype analyses.
Statistical analysis. To assess pairwise differences in sensitivity and
specificity, P values were determined by Student’s t test using GraphPad
Prism 6.0 (GraphPad, La Jolla, CA). P values for comparative analyses of
all four tests were determined using analysis of variance (ANOVA)
(GraphPad). Confidence intervals were calculated by the modified Wald
method (GraphPad).
This study was approved by the Institutional Review Board of the
University of North Carolina at Chapel Hill.
RESULTS
Method comparison. The archived retrospective specimens were
selected to challenge the sensitivities of the assays. Positive NP
specimens were selected to represent as many of the targets as
possible. Of 200 specimens, 161 (80.5%) were consensus positives
(e.g., positive for at least one of the viruses detectable by at least
two platforms). The consecutive arm of the study was designed to
simulate real laboratory conditions during a period of relatively
high respiratory disease and to moderate the bias that is inherent
in using archived specimens for comparative studies. Of the 100
consecutive NP swabs, 38 were positive for at least one of the
detectable viruses, as follows: AdV (n  3), influenza virus A/H3
(n  1), MPV (n  10), PIV1 (n  2), RSV (n  8), and RhV/EV
(n  17). No influenza virus B, PIV2, or PIV3 positives were
detected during this study period. Since positive specimens were
limited during the consecutive arm, the sensitivity and specificity
analyses were performed using all specimens combined (n  300).
The sensitivity data for the four multiplex respiratory virus assays
are summarized in Table 2.
The FilmArray RP had sensitivities greater than 92% for the
following targets: influenza virus A/H3, MPV, PIV1, PIV2, PIV3,
and RSV B. However, AdV (57.1%), influenza virus A H1/2009




FilmArray RPc BioFire Diagnostics Endpoint melt curve analysis No AdV; CoV HKU1, NL63; influenza virus A (H1/2009, H1, H3);
influenza virus B; MPV; PIV1, -2, -3, -4; RSV; RhV/EV
eSensor RVP GenMark Dx Voltammetry Yes AdV (C, B/E); influenza virus A (H1/2009, H1, H3); influenza
virus B; MPV; PIV1, -2, -3; RSV (A/B); RhV
xTAG RVPv1 Luminex Molecular
Diagnostics
Fluorescence-labeled bead array Yes AdV; influenza virus A (H1, H3); influenza virus B; MPV;
PIV1, -2, -3; RSV (A/B); RhV/EV
xTAG RVP fast Luminex Molecular
Diagnostics
Fluorescence-labeled bead array Yes AdV; influenza virus A (H1, H3); influenza virus B; MPV;
RSV; RhV/EV
a All four panels are FDA cleared for testing on NP swabs only.
b AdV, adenovirus; CoV, coronavirus; MPV, metapneumovirus; PIV, parainfluenza virus; RSV, respiratory syncytial virus; RhV, rhinovirus; EV, enterovirus.
c Note that, after the completion of this study, the FilmArray RP was FDA cleared for additional targets which were not assessed in our study, including CoV HKU1 and NL63,
Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae.
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(73.3%), influenza virus B (77.3%), RSV A (86.4%), and RhV/EV
(83.7%) were detected with less sensitivity by the FilmArray. As we
had no comparator method for the coronaviruses or PIV4, these
targets were not included in the analysis. The eSensor RVP sensi-
tivities were 100% for all targets with the exception of RhV
(90.7%). The sensitivities of xTAG RVPv1 were greater than 92%
for all targets except AdV (74.3%) and RSV A (86.4%). The RVP
fast version of the assay was less sensitive overall; all targets
showed 92% sensitivity, with the exception of MPV (100%) and
RhV/EV (93.0%). Since the xTAG RVP fast does not detect PIV1,
PIV2, or PIV3, we could not assess their individual performance
on this platform.
Specificities were high for all assays. The FilmArray RP was
100% specific for all targets (95% confidence interval [CI], 96.2,
100). The eSensor recorded false-positive results for AdV (n  3),
influenza virus B (n  1), MPV (n  2), PIV2 (n  2), RSV B (n 
2), and RhV (n  7). Sporadic false-positive signals were detected
by the xTAG RVPv1 and xTAG RVP fast for AdV (1 each), MPV (1
each), and RhV (xTAG RVPv1, n  2, and xTAG RVP fast, n  1).
The overall specificities (95% CIs) for the eSensor RVP, xTAG
RVPv1, and xTAG RVP fast tests were 99.2% (95.4, 100), 99.8%
(96.0, 100), and 99.9% (96.1, 100), respectively.
Coinfections. Thirty samples were dually positive, and one was
positive for three viruses, representing a coinfection rate of 10%.
Twenty-one of the dual positives involved RhV/EV. Specific de-
tails on the coinfections identified by each platform can be found
in Table 3. Overall, the eSensor RVP detected the most coinfec-
tions (96.8%), followed by the xTAG RVPv1 (71.0%), FilmArray
RP (61.3%), and xTAG RVP fast (54.8%).
Adenovirus. The greatest variability observed was for AdV de-
tection. All AdV-positive samples (n  35) were typed by sequenc-
ing the hexon gene. Samples with low levels of virus (determined
by LDT cycle threshold [CT] values of 35) were not able to be
typed (n  4). These four samples were not detected by the xTAG
RVPv1, xTAG RVP fast, or FilmArray RP but were detected by the
eSensor RVP and our adenovirus LDT (Table 4). The eSensor RVP
detected 100% of adenovirus-positive specimens and accurately
identified them as species C or species B/E when compared to the
results of hexon gene sequencing. With 57.1% sensitivity for AdV
detection, the FilmArray RP detected all of the AdV type 3 and 4
TABLE 2 Sensitivity per target for each of the four respiratory viral panels as determined using NP swabs
Virus
No. of true-positive specimens
(n  300 specimens tested)
% Sensitivity (95% CI) of:
FilmArray RP eSensor RVP
xTAG
RVPv1 RVP fast
AdV 35 57.1 (40.8, 72.0) 100 (88.2, 100) 74.3 (57.8, 86.0) 82.9 (66.9, 92.3)
Influenza virus
A 30 86.2a (68.8, 95.1) 100 (86.5, 100) 100 (86.5, 100) 86.7 (69.7, 95.3)
A H1/09 16 73.3a (47.6, 89.5) 100 (77.3, 100) 100 (77.3, 100) 81.3 (56.2, 94.2)
A H3 14 100 (74.9, 100) 100 (74.9, 100) 92.9 (66.5, 99.9) 78.6 (51.7, 93.2)
B 22 77.3 (56.2, 90.3) 100 (82.5, 100) 95.5 (76.5, 99.9) 45.5 (26.9, 65.4)
MPV 26 96.2 (79.6, 99.9) 100 (84.8, 100) 100 (84.8, 100) 100 (84.8, 100)
PIV
1 14 100 (74.9, 100) 100 (74.9, 100) 100 (74.9, 100) NAb
2 13 92.3 (64.6, 99.9) 100 (73.4, 100) 100 (73.4, 100) NA
3 13 100 (73.4, 100) 100 (73.4, 100) 100 (73.4, 100) NA
RSV
A 22 86.4 (65.8, 96.1) 100 (82.5, 100) 86.4 (65.8, 96.1) 86.4 (65.8, 96.1)
B 14 100 (74.9, 100) 100 (74.9, 100) 92.9 (66.5, 99.9) 85.7 (58.8, 97.2)
RhV/EV 43 83.7 (69.7, 92.2) 90.7 (77.8, 96.9) 93.0 (80.7, 98.3) 93.0 (80.7, 98.3)
a One sample tested as equivocal and is not included.
b NA, not applicable.
TABLE 3 Combinations of multiple viruses identified during the study
and how many instances were detected by each assay
Viral combinationb













AdV  InfA H1/2009 0 1 0 0 1
AdV  MPV 0 1 0 1 1
AdV  PIV2 1 1 1 NAa 1
AdV  RhV/EV 4 6 5 5 6
AdV  RSV A 1 4 2 3 4
InfA H1/2009  RhV/EV 1 1 1 1 1
InfA H1/2009  RSV B 1 2 2 2 2
MPV  RhV/EV 1 1 1 1 1
PIV1  RhV/EV 2 1 1 NA 2
PIV2  RhV/EV 2 4 3 NA 4
PIV3  RhV/EV 0 1 0 NA 1
RSV A  RhV/EV 5 5 5 4 5
RSV B  RhV/EV 1 1 1 0 1
AdV  MPV  RSV A 0 1 0 0 1
Total 19 30 22 17 31
a NA, not applicable.
b InfA, influenza virus A.
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specimens but only detected 4 of 7 of AdV type 1, 2 of 7 of AdV
type 2, 1 of 3 AdV type 5, and 1 of 2 AdV type 21 specimens. The
xTAG RVPv1 detected all of the AdV type 4 and 21 and 5 of 7 AdV
type 1, 6 of 7 AdV type 2, 7 of 8 AdV type 3, and 2 of 3 AdV type 5
specimens, while xTAG RVP fast missed one specimen each of
AdV type 1 and AdV type 3.
Rhinovirus/enterovirus. The FilmArray RP and the xTAG as-
says show cross-reactivity between RhV and EV, while the eSensor
RVP is specific for RhV. Therefore, we investigated whether the
90.7% eSensor sensitivity for RhV was due to the lack of EV cross-
reactivity. We tested false-negative eSensor RVP RhV specimens
using our enterovirus-specific LDT. Three of 4 (75%) false-nega-
tive eSensor RVP RhV specimens were positive by our enterovirus
LDT. Therefore, these do not represent false negatives for RhV
detection.
Age group-specific performance. We compared the overall
sensitivities and specificities for each platform by age groups: 5
years, 6 to 11 years, 12 to 17 years, and 18 years. The eSensor
RVP did not have any statistically significant differences by age
group, and none of the assays showed differences in specificity by
age group. The xTAG RVP fast and FilmArray RP both showed
higher sensitivities for the 18-year age group than for the 18-
year age group (xTAG RVP fast, 89.8% versus 81.5% [P  0.038],
and FilmArray, 91.9% versus 80.6% [P  0.004]). The FilmArray
RP also demonstrated different sensitivities for the 5-year age
group and the 18-year age group (80.2% versus 91.1%; P 
0.01). For the xTAG RVPv1, the age group that had the lowest
sensitivity (85.5%) was the 5-year group, and this was signifi-
cantly different than the sensitivities of the 6- to 17-year (100%;
P  0.001) and the 18-year (97.3%; P  0.002) groups.
DISCUSSION
Without doubt, the commercial availability of multiplex molecu-
lar respiratory viral panels represents a significant advancement in
the laboratory diagnosis of respiratory viral illnesses. Nonetheless,
each system has its advantages and disadvantages, and each user
should determine which system is appropriate for their specific
laboratory and/or patient population. Since not all laboratories
are able to do a side-by-side study of the four FDA-cleared molec-
ular respiratory viral panels, we have attempted to demonstrate
the relative performance of each assay, including a workflow as-
sessment. Table 5 shows the four assays as they compare in terms
of hands-on time, time to result, and number of steps (as an indi-
cator of ease of use).
BioFire’s FilmArray RP was the easiest to use and had the
shortest time to result. For MPV, influenza virus A/H3, PIV1,
PIV2, PIV3, and RSV B, its sensitivities were 92%, whereas the
sensitivities for AdV, influenza virus A/H1N1/2009, influenza vi-
rus B, RSV A, and RhV/EV were lower. The assay’s AdV sensitivity
was significantly lower than those of the eSensor (P  0.0001) and
xTAG RVP fast (P  0.05) but similar to that of the xTAG RVPv1
(P  0.13); its influenza virus A/H1N1/2009 sensitivity was lower
than those of the eSensor and xTAG RVPv1 (P  0.05) but com-
parable to that of the xTAG RVP fast (P  0.67); and its influenza
virus B sensitivity was lower than that of the eSensor (P  0.05)
only. However, the FilmArray RP was significantly more sensitive
than the xTAG RVP fast for influenza virus B (P  0.05), and there
were no statistically significant differences in sensitivity rates be-
tween the assays for RSV A or RhV/EV. The FilmArray RP was
100% specific. An extended FDA-cleared panel of 20 targets is now
available that includes Chlamydophila pneumoniae, Mycoplasma
pneumoniae, and Bordetella pertussis, making the FilmArray RP
the panel with the most targets and the only one to include bacte-
rial targets. We did not assess the performance of these additional
targets in this study. As the only closed system in our study and the
only system to provide only qualitative results, the FilmArray RP is
amenable to testing outside a dedicated high-complexity molecu-
lar laboratory and is appropriately labeled by the FDA as being of
moderate complexity. This is in contrast to the other three panels
evaluated in this study that are FDA cleared as high-complexity
tests and are not closed systems. On the downside, each FilmArray
instrument can only test one sample at a time, limiting its capacity
for high-throughput testing and requiring the need for more than
one instrument in most laboratories.
The GenMark eSensor RVP was the most sensitive of the four
assays, detecting 100% of the samples known to be positive for
AdV, influenza virus A, influenza virus B, MPV, PIV1, PIV2,
PIV3, RSV A, and RSV B. The eSensor RVP is the only assay to
report adenovirus species (AdV C or AdV B/E), doing so with
100% accurate results compared to our sequencing results. How-
ever, the loss of enterovirus detection is a potential limitation,
particularly for laboratories that routinely test for enteroviruses in
respiratory specimens. The increased sensitivity of the eSensor
RVP is countered by a lower specificity than the other three assays
(P  0.05). Whether the false positives represent increased ana-
TABLE 4 Results by adenovirus type and platforma
AdV type









1 4 7 5 6 7
2 2 7 6 7 7
3 8 8 7 7 8
4 4 4 4 4 4
5 1 3 2 3 3
21 1 2 2 2 2
Untypeable 0 4 0 0 4
All 20 35 26 29 35
a The reference method was an adenovirus LDT.
TABLE 5 Workflow analysis of the four platforms
Parameter







Off-board extractionb No Yes Yes Yes
No. of steps 1 3 5 2
Hands-on time 0.05 0.92 1.2 0.75
Instrument time 1.1 5.0 5.5 2.75
Time to assay
completion
1.1 6.0 6.6 3.5
Total time to result 1.2 7.2 7.8 4.8
No. of samples processed
in 8 h per instrument
7 21 21 21
a Times are per sample for FilmArray RP and per batch for eSensor RVP, xTAG RVPv1,
and xTAG RVP fast.
b Off-board extraction was done with the bioMérieux EasyMag, which has a hands-on
time of 30 min and total extraction time of 77 min.
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lytical sensitivity, greater variability in assay performance, or the
ease with which runs can be contaminated cannot be determined.
Although the eSensor RVP does provide a quantitative value in
nanoamps (nA), the package insert states that it is not intended to
provide a quantitative value for the virus present. Furthermore,
Pierce and Hodinka concluded that an accurate quantitative cor-
relation between real-time PCR CT values and nA signal strength
could not be made (9). Similarly, our observed nA signal strengths
for false positives were not statistically different from those ob-
tained for true positives. The workflow for the eSensor RVP is a
slight improvement over that of the predicate xTAG RVPv1, with
two fewer steps and less hands-on time. However, the time to
result is still over 7 h, and postamplification material is still
manipulated, increasing the risk of laboratory contamination.
The eSensor RVP is best suited for batched testing in a high-com-
plexity laboratory with significant molecular experience.
xTAG RVPv1 was the first large multiplex panel cleared by the
FDA. With multiple steps, it had the longest hands-on time and
longest time to result. Although its sensitivities for AdV (74%) and
RSV A (86%) were somewhat lower, there was no statistical dif-
ference between the xTAG RVPv1 and the FilmArray RP or xTAG
RVP fast for AdV, and there were no statistical differences in RSV
A sensitivities between any of the tests (P  0.81). Similar to the
eSensor RVP, the xTAG RVP assay provides quantitative results in
median fluorescent intensity (MFI) units, but the test is only in-
tended to provide qualitative results, and we have observed that
these MFI units are not linear compared to the CT values of real-
time PCR (data not shown). However, specimens with high titers
of PIV3 also caused a positive PIV1 signal; thus, the ratio of these
signals must be assessed in determining PIV3 calls. The xTAG
RVPv1 is best utilized as a batched test performed in an experi-
enced molecular laboratory, as there are multiple steps where po-
stamplification material is manipulated.
Although the xTAG RVP fast does decrease the time to result
by 3 h relative to the xTAG RVPv1 and reduces the number of
hands-on steps, it does not offer PIV detection, and there is a
significant drop in overall sensitivity. The sensitivities were below
92% for all targets but MPV and RhV/EV, and importantly, the
influenza virus B sensitivity was 45.5%. There were minimal spec-
ificity concerns with the xTAG RVP fast.
It is known that the detection of adenovirus presents a signifi-
cant challenge to the molecular multiplex tests. While not all cause
respiratory infection, there are presently 57 recognized human
adenovirus serotypes. Based on the respective package inserts, the
xTAG RVPv1 has decreased detection for species C (serotypes 1, 2,
5, and 6) and serotypes 7A (species B) and 41 (species F), while the
FilmArray RP has decreased detection of serotypes 2 and 6 (species
C). Thus, the lower sensitivities we observed for these two assays
are not surprising, though the 57.1% sensitivity we observed for
the FilmArray RP is significantly lower than what is stated in the
package insert (88.9%). Although the FilmArray RP did miss five
AdV serotype 2 specimens, it also missed three serotype 1 speci-
mens, two serotype 5 specimens, and four specimens that were
unable to be typed due to low viral quantity (Table 4). The ob-
served sensitivity of the xTAG RVPv1 for adenovirus (74.3%) is
very similar to the package insert data of 78.3%. The serotypes of
AdV missed by the xTAG RVPv1 were 1, 3, 5, and untypeable
(Table 4). The risk of offering a test with lower sensitivity for
adenovirus will be dependent on the patient population served
and whether additional testing for adenovirus is offered.
The xTAG RVPv1 and xTAG RVP fast will subtype influenza
virus A-positive samples as seasonal H1 or seasonal H3. The
eSensor RVP and FilmArray RP will also subtype H1N1/2009.
Two specimens positive for the influenza virus A matrix gene only
(subtype negative) by xTAG RVP and xTAG RVP fast were actu-
ally seasonal H3, as established by the other tests and confirmed by
the Prodesse ProFAST assay. Four samples initially showed in-
fluenza virus A-positive/subtype-negative results by the eSensor
RVP. All four were lower-level positives (nA of 44.7 to 59.0; for all
positives, the mean nA was 152.6 [95% CI of 135.2, 167.1]). As
recommended by the package insert, the samples were tested
again, and all were negative. With the disappearance of seasonal
H1 (which was oseltamivir resistant), there is not currently a clin-
ical need to offer influenza virus A subtype information. However,
subtype information is helpful for our epidemiology and infection
control colleagues, and it may prove to be beneficial should dif-
ferences in antiviral susceptibility develop.
Our study is partially limited by the inability to do a true pro-
spective study. Unfortunately for the study, the respiratory season
(2011-2012) during which the study was performed was not as
robust as past seasons, including the noticeable absence of signif-
icant numbers of influenza virus-positive specimens. Therefore,
the numbers per target included in the consecutive study are rel-
atively low, making it difficult to ascertain the significance of dif-
fering performance among the assays in a true clinical setting.
However, the same trends in sensitivity were observed in both the
retrospective specimens and the archived, consecutive specimens
(e.g., lower adenovirus and RSV sensitivities [data not shown]).
Furthermore, the extended freezer time and freeze-thaw cycle for
some of the specimens could affect assay performance. To mini-
mize any differential effect on assay performance, we tested
thawed specimens on all four platforms simultaneously and did
not use a retrospective reference result, but it should be noted that
such results may vary from the results for freshly obtained speci-
mens that have not been frozen.
Another limitation is the use of a composite gold standard.
Ideally, individual LDTs for each target would also be performed
on every specimen to establish the reference result, but this was
not possible in our laboratory due to the lack of LDTs for every
target, as well as financial constraints. Thus, we used “positive by
at least two platforms” as the reference result by which we calcu-
lated sensitivity and specificity. As such, an assay with greater sen-
sitivity than all other assays tested would show lower specificity.
There is also inherent bias associated with selecting archived spec-
imens for comparative studies. The frozen specimens had primar-
ily been tested with the xTAG RVPv1, although we did attempt to
select as many specimens as possible that had been tested by LDTs.
Thus, the retrospective sensitivity data may favor the xTAG
RVPv1. Lastly, the eSensor RVP assay that was used was the re-
search-use-only (RUO) version, as the assay had not yet been FDA
cleared at the time of this study. We did not, however, analyze any
RUO targets in the present work and note that the chemistry for
target detection and the threshold for positivity (3 nA) are the
same as for the in vitro diagnostics version. Even considering the
study limitations, we assert that this head-to-head comparison of
the four commercially available respiratory viral panels provides
useful information regarding the relative performance of each
assay.
Lastly, a significant consideration for clinical laboratories is the
comparison of the relative costs of these assays. Although there is
Popowitch et al.
1532 jcm.asm.org Journal of Clinical Microbiology
a paucity of data regarding the cost effectiveness of implementing
molecular multiplex testing for respiratory viruses, Mahony et al.
(23) demonstrated a Can$291 per inpatient cost saving by elimi-
nating testing algorithms and using a molecular multiplex assay as
the primary test. Although all three platforms require specialized
instrumentation, none of the vendors require that the equipment
be a capital purchase. In terms of reagents, the relative costs are
FilmArray RP  eSensor RVP  xTAG RVPv1. This is also the
order for the number of targets offered. However, note that the list
is reversed when ranking hands-on time (Table 5). When all ex-
penses are considered, the three competitive multiplex assays offer
nearly the same cost per target. Therefore, when considering an
FDA-cleared multiplex respiratory panel, it is important to focus
on what is best for your patient population and your laboratory.
Future generations of these tests and/or the development of new
products promise to improve the ability to offer accurate, rapid,
and cost-effective laboratory diagnoses for respiratory tract ill-
nesses.
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